131 Dartmouth Street
3rd Floor
Boston, MA 02116
United States
650 503 9095
https://www.adicetbio.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 143
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Aya Jakobovits Ph.D. | Founder & Independent Director | 45k | N/A | 1955 |
Mr. Brian Nicholas Harvey | Chief Financial Officer | 594.94k | N/A | 1961 |
Dr. Donald Healey Ph.D. | Chief Technology Officer | 606.34k | N/A | 1962 |
Dr. Blake Aftab Ph.D. | Senior VP & Chief Scientific Officer | 675.04k | N/A | 1981 |
Ms. Amy Locke | Chief Human Resource Officer | N/A | N/A | N/A |
Dr. Francesco Galimi M.D., Ph.D. | Chief Medical Officer & Senior VP | 680.37k | N/A | 1968 |
Dr. Nancy L. Boman M.D., Ph.D. | Senior VP & Chief Regulatory Officer | N/A | N/A | N/A |
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.
Adicet Bio, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 6; Board: 9; Shareholder Rights: 8; Compensation: 9.